ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

ProteoTech is dedicated to discover disease-modifying treatments for major human diseases. Since 1996, ProteoTech has been on a journey of discovery for novel small molecule compounds and peptide therapeutics that will result in a positive impact on the world's aging population.

 

The cost of such devastating diseases is significant and growing larger every year. The impact this will have on a person and their family's quality of life is real and ever-growing. ProteoTech's scientists are dedicated to improving the health of these individuals suffering from these dreaded diseases.

News

November 11, 2008
ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference

 

August 07, 2008
ProteoTech's Exebryl-1® Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

 

July 29, 2008
Exebryl-1® Phase I Human Clinical Trial for Alzheimer's disease commences

 

July 25, 2008
ProteoTech to present at International Alzheimer's Conference—Chicago, IL.

 

May 28, 2008
ProteoTech receives clearance from FDA to proceed with Phase I Human Clinical Trials for Exebryl-1®

 

May 15, 2008
ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

 

April 28, 2008
ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease